Forgot Password

Board of Directors.jpegExecutive

Andrew Larke - Chairman

After commencing his career as a lawyer, over the last 25 years Andrew has held a number of senior corporate finance, strategy, business development and M&A roles within large Australian corporations.

Most recently he was Global Head of Strategy and Mergers & Acquisitions at Orica Limited, before becoming CEO and then Chairman of Ixom (formerly Orica’s chemicals business, now owned by Blackstone private equity).

Andrew is also a Director of the following:

  • DuluxGroup Limited
  • Diversified United Investment Limited
  • L1 Long Short Fund Limited
  • Sand Hill Road hospitality group

Dr Gareth Gregory - Medical Director


Dr Gareth Gregory is Medical Director at Cell Care and a Consultant Haematologist at Monash Health. He was awarded fellowships of the Royal Australasian College of Physicians and Royal College of Pathologists of Australasia after completing training in general haematology and stem cell transplantation at Monash Health, the Alfred Hospital, Royal Perth Hospital and the Australian Red Cross Blood Service.

Dr Gregory is passionate about improving outcomes for patients through translational research of novel therapies and stem cell applications and has many publications in high impact medical journals for both his clinical and preclinical contributions. He was awarded the prestigious Albert Baikie Memorial Medal by the Haematology Society of Australia and New Zealand for his PhD studies investigating novel therapies for the treatment of lymphoma at the Peter MacCallum Cancer Centre and University of Melbourne. Dr Gregory is an alumnist of the European Hematology Association Clinical Research Training in Hematology program and is actively involved in translational and clinical research within the Monash Health Translation Precinct including as principal investigator for numerous clinical trials.

Dr Gregory is a fellow of the Haematology Society of Australia and New Zealand, American Society of Hematology, European Hematology Association and member of the Australasian Leukaemia and Lymphoma Group, Australasian Lymphoma Alliance and Australian T-cell Lymphoma Network.

Brent Dennison - Chief Executive Officer

Brent was most recently involved in the launch of Mothercare in Australia, and was CEO of that business until June 2012. Prior to that, Brent worked in Europe in the private equity industry for 6 years, focusing on growth opportunities and international expansion. Before moving to Italy, Brent was a director with Citigroup in New York investing in growth financial services businesses of strategic interest to the bank. Ahead of joining Citigroup, Brent led two entrepreneurial ventures; a UK-based software business and the launch of Turkey's first management consulting practise in the late 1990s. Before embarking on entrepreneurial pursuits, Brent was a strategy consultant with the Boston Consulting Group in Melbourne and New York.

Paula Butler – Chief Financial Officer

Paula has held a number of management roles in Finance and Operations throughout her career. These have spanned a range of industries including blue chip professional services through to the not for profit sector, including KPMG, Arthur Anderson, Planet Hollywood, Igloo Zoo and Surf Life Saving Australia.

Paula has also held a lecturing role at Southern Cross University as part of their Masters of Practicing Accountants. Paula holds a Bachelor of Economics (Accounting) and is a Certified Practicing Accountant.

CPE Capital

Cell Care is majority owned by funds managed by CPE Capital (formerly CHAMP Private Equity).

CPE Capital and its affiliated fund entities have deployed approximately A$3.8 billion of investor commitments since 1987. CPE Capital has one of the largest dedicated buyout teams in the region and is Australasia’s most experienced private capital manager, having made 75 platform investments during its 32 year history. CPE Capital undertakes control buyout transactions, enters into founder partnerships and provides growth investments for mid-market companies in Australasia, including those which possess significant offshore operations or ambitions.

For more information visit